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hippocampus dose was Dmax less than 17Gy without 
compromising the coverage of planning target volume (PTV) 
and other organs at risk were prioritized over hippocampal 
constraint. The mini-mental state examination (MMSE) and 
Seoul verbal learning test for total recall, delayed recall and 
recognition (SVLT-TR, DR, R) were performed at baseline and 
at 7 and 13 or 16 months after radiotherapy.  
 
Results: A total of 41 patients were accrued. Median age was 
48 years (range 26-76) and 51.2 % of the patients were male. 
Eighteen patients (43.9%) had WHO grade I or II tumor 
whereas 23 patients (56.1%) had grade III or IV tumor. Median 
volume of PTV was 192.8 cc (range 33.4-522.6) and median 
prescribed dose was 60Gy (range 46-66). Concurrent 
chemotherapy was given to 18 patients (43.9%). Median 
D100% and Dmax to the contralateral hippocampus were 
7.7Gy (range 0.6-24.8) and 16.6 Gy (range 3.56-60.4) 
respectively. Mean dose to contralateral hippocampus could 
be spared to less than 21 Gy in 39 patients with median value 
of 11.6 Gy (range 0.3-37.3) which was lower compared to 
previous documentation. Median value of maximal dose to 
lenses and eyeballs were 4.3 Gy (0.4-8.1) and 13.7 Gy (0.5-
46.6) respectively. At median follow up of 7.8 months (range 
0-14.8), median progression-free survival and overall survival 
were not reached. Cognitive function tests at 7 months were 
analyzable in 12 patients. For these patients, MMSE, SVLT-TR, 
SVLT-DR and SVLT-R at 7 months showed improved results 
compared to the baseline with 2.0% (95% CI, -0.8% to 4.7%), 
11.0% (95% CI, 3.3% to 18.8%), 20.1% (-5.5% to 45.8%) and -
0.6% (95% CI, -6.6% to 8.2%) increase respectively. No grade 4 
or 5 toxicity was reported.  
 
Conclusion: Hippocampus could be spared effectively in 
radiotherapy to primary brain tumors using VMAT. Despite 
limited follow up data, cognitive function tests of the 
patients showed promising results. Further follow up data 
would clarify the effect of hippocampal sparing on the 
cognitive function of the patients treated with radiotherapy 
for primary brain tumor.  
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Purpose or Objective: To analyze pre-treatment MRI- and 
18F-fluoroethylthyrosine-PET- (FET-PET) based target 
volumes and patterns of failure following radiotherapy (RT) 
with concurrent temozolomide (TMZ) for primary 
glioblastoma multiforme (GBM). 
 
Material and Methods: Thirty-four patients with primary GBM 
were treated using MRI based treatment volumes (GTVrm). 
Before treatment patients underwent FET PET/CT scans and 
biological tumor volume (GTVpet) were contoured but not 
used for target definition. Progression were defined 
according to RANO criteria. Tumor progression and pre-
treatment MRI and PET scans were co-registered to the 
radiation dose map. Failures were classified based on 
location of primary GTVs and dose delivered at the site of 
failure. We investigated volumetric size and uniformity of 
MRI- vs. FET-PET/CT-derived GTVs and progression patterns 
assessed by means of FET PET/CT and MRI. 
 
Results: FET-PET based GTVs measured 10 minutes after 
radionuclide injection (a.r.i.) (median 37.3 cm3) were larger 
than GTVs measured 60 minutes a.r.i. (median 27,7 cm3). 
GTVpet were significantly larger than corresponding MRI 
based GTVs (median 19,3 cm3). The congruence of MRI and 
FET signals for the identification of glioblastoma GTVs is poor 
with mean uniformity index of 0.4 (p=0,0). 74% of failures 
were located inside primary GTVpet. 68% of failures occured 
within the 95% isodose line, and 9% within 60 Gy isodose. 
 
Conclusion: The size and geometrical location of GTVs 
differed in a majority of patients. The volume of GTVpet 
depends on time a.r.i. Tumor progression were mostly inside 
FET-PET volumes. FET PET better defined failure site then 
MRI. Finally dose inhomogenity inside GTVpet and GTVrm and 
favourable tumor control within 60Gy isodose advocates 
further studies with PET-MR based high-dose radiation 
therapy of GBM. 
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Purpose or Objective: Temozolomide (TMZ) based 
chemoradiotherapy defines the current gold standard for the 
treatment of newly diagnosed glioblastoma. Data regarding 
the influence of TMZ dose density during chemoradiotherapy 
are currently not available. We retrospectively compared 
outcomes in patients receiving no TMZ, patients receiving 
TMZ during radiotherapy on radiotherapy days only (5/7) and 
patients receiving TMZ constantly 7 days a week (7//7).  
 
Material and Methods:  
From 2002 to 2012 a total of 432 patients with newly 
diagnosed glioblastoma received radiotherapy in our 
department. 118 patients had radiotherapy alone, 210 had 
chemoradiotherapy with temozolomide (75 mg/m²) daily (7/7 
days a week) and 104 chemoradiotherapy with temozolomide 
only on radiotherapy days (5/7 days a week, Monday till 
Friday). Radiotherapy was applied in 30 fractions to a total 
dose of 60 Gy. 
 
Results: Median survival after radiotherapy alone was 9.1 
months, compared to 12.6 months with temozolomide 5/7 
and to 15.7 months with temozolomide 7/7. The 1 year 
survival was 33% in the radiotherapy only group, 52% in the 
5/7 group and 64% in the 7/7 group. Kaplan Meier analysis 
showed a significant improvement of temozolomide 7/7 vs. 
5/7 (p=0.01 by the log-rank test), while temozolomide 5/7 
was still superior to no temozolomide at all (p=0.02). 
 
Conclusion: Our results confirm the findings of the 
EORTC/NCIC-trial by Stupp et al., establishing the daily 
temozolomide chemoradiotherapy as standard therapy for 
glioblastoma. Also a reduced temozolomide scheme can at 
first prolong the survival of glioblastoma patients, but not as 
much as the daily application. 
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Purpose or Objective: We aimed to identify subventricular 
zone (SVZ)-related prognostic factors of survival and patterns 
of relapse among patients with glioblastoma. 
 
Material and Methods: Forty-three patients with primary 
diagnosed glioblastoma treated in our Cancer Center 
between 2006 and 2010 were identified. All patients received 
surgical resection, followed by temozolomide-based 
